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Immunoadsorption in the sensitized transplant recipient
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Case presentation
A 36-year-old woman had developed insulin-dependent diabetes
mellitus at age 7. During her first pregnancy, 19 years later, she was
hypertensive and had proteinuria. This pregnancy and two further
pregnancies 3 years later were unsuccessful (2 stillbirths and I perinatal
death). Seven years later, she had a plasma creatinine of 453 mol/liter
(5.1 mg/dl) and was blind in her right eye from a retinal detachment and
glaucoma.
One year later she started continuous ambulatory peritoneal dialysis
(CAPD) and 2 months later she received a kidney from her sister. Prior
to transplantation, she had received 5 units of blood and her percentage
reactivity rose from 0% to 26%. The donor kidney was mismatched for
3 class-I HLA antigens (Al, B47, B 17). Initially the graft functioned,
and at 2 weeks, her plasma creatinine was 200 mol/liter (2.3 mgldl).
She was given prednisolone and azathioprine. Despite anti-rejection
therapy, she lost her kidney because of irreversible rejection 4 months
after transplantation. Following graft nephrectomy, her percentage
reactivity rose to 94%.
The patient returned to CAPD for the next 3 years. During that time,
peritonitis and an abdominal hernia developed, prompting abandon-
ment of CAPD. She then started hospital-based hemodialysis. Her
anemia worsened and she became transfusion dependent. She tolerated
hemodialysis poorly and transplantation was reconsidered.
The patient was blood group A and had been highly and persistently
sensitized since the loss of her previous graft. Her percentage reactivity
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had remained greater than 90%, and the main HLA antibody specific-
ities were Al, All, and possibly Bw4. Th HLA-Al titer was 1/64.
Non-HLA autoantibodies had been excluded. As a result, the chance
that a suitable graft would become available was extremely remote, and
the decision was made to remove her HLA antibodies by extracorpo-
real immunoadsorption prior to transplantation.
Following the first course of extracorporeal immunoadsorption, her
HLA-A 1 antibody became undetectable and her percentage reactivity
fell to 32%. Despite immunosuppression with prednisolone and cyclo-
phosphamide, however, she resynthesized the HLA antibodies and
required an additional two courses of extracorporeal immunoadsorption
over a 4-month period while waiting for a kidney. One month after her
last course of immunoadsorption, she received a kidney carrying none
of the HLA antigens against which she had previously generated
antibody. The crossmatch was positive with the pretreatment sera but
negative with the posttreatment sera.
After transplantation she was given prednisolone, cyclosporine, and
azathioprine; she also received a 10-day course of prophylactic antithy-
mocyte globulin. The graft functioned immediately, and at 3 months
after transpb"itation, her plasma creatinine was 126 molIliter (1.4
mg/dl). At 8 months, following an upper respiratory tract infection, the
plasma creatinine rose to 240 mol/liter (2.7 mg/dl). Allograft biopsy
showed acute vascular rejection. No donor-specific antibodies were
detected. She was treated with high-dose steroids and a 10-day course
of OKT3, following which her plasma creatinine fell to 160 smo1/liter
(1.8 mgldl). She is now well with a plasma creatinine of 175 tmo1/liter
(2.0 mgldl), one ye after transplantation.
Discussion
DR. DAVID TAUBE (Consultant Nephrologist, St. Mary's
Hospital, London): This patient exemplifies the problems of
highly sensitized renal transplant recipients as well as a new
approach to their treatment. These unfortunate patients, in
whom successful transplantation is difficult to achieve, accu-
mulate in end-stage renal failure programs with the attendant
misery and financial burdens of long-term dialysis. The scale of
the problem is demonstrated by the recent estimate that 20% of
the 20,000 dialysis patients awaiting transplantation in Europe
and North America are sufficiently sensitized to virtually pre-
clude transplantation [1]. I will begin by discussing the causes
and consequences of sensitization and then will describe new
strategies for managing these patients before and after renal
transplantation. Although the term "sensitized patient" gener-
ally is used to describe the patient who has "preformed" HLA
antibodies, I will briefly discuss other important, non-HLA
antibodies, which include lymphocytotoxic autoantibodies, en-
dothelial-monocyte antibodies, and blood group antibodies as
well.
Documenting sensitization
The human kidney expresses class-I and, variably, class-I!
HLA antigens [2]. Therefore it is not surprising that the
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majority of patients with HLA antibodies damage grafts ex-
pressing the appropriate HLA antigens. This phenomenon was
recognized in the early days of transplantation in 1965 and 1966,
when Terasaki et a! [3] and Kissmeyer-Nielsen and coworkers
[4] showed that the presence of anti-graft HLA antibodies
before transplantation was associated with "hyperacute" rejec-
tion [4]. Anti-graft antibodies are detected by complement-
dependent lymphocytotoxicity (CDC) tests with peripheral
blood lymphocytes, purified T and B cells or monocytes, and
endothelial cells acting as targets. Sera from patients awaiting
transplantation are screened regularly with panels of HLA-
typed donor lymphocytes, selected to ensure representation of
all defined class-I HLA antigens. The proportion of the panel's
cells that the patient's serum kills is expressed as the percent-
age reactivity. The specificity of the antibody is determined
from the HLA type of the donor lymphocytes. Patients with
percentage reactivities of 0% to 10% are defined as being
nonsensitized; with 10% to 50%, as sensitized; and with 50% to
100%, as highly sensitized. The sensitivity of these tests can be
increased by the use of anti-human globulin [5, 6] and flow
cytometry [7—91. Flow cytometry can be of particular value in
detecting small amounts of HLA antibodies not found by
conventional CDC testing, amounts that nonetheless can lead to
subsequent graft failure [8]. The overall value of these two
techniques in terms of predicting graft outcome is currently
uncertain, however [10, 11].
The HLA antibodies, usually IgG, are mainly directed against
class-I HLA antigens [9]. In a recent study of 150 sensitized
patients awaiting transplantation, 50% had class-I HLA anti-
bodies, whereas only 10% had class-Il HLA antibodies [121.
Two types of HLA antibodies are found in sensitized patients.
Most patients have antibodies directed against cross-reactive
groups of HLA class-I antigens similar to those detected in the
sera of multiparous women [13—151. The classic cross-reactive
groupsincludeAl,3, 11;A2,28,9;B5, 15, l8,w35;B22,7,27,
40; and B21, 12, 13 [16]. These antibodies are directed against
shared public determinants on the HLA class-I heavy chain [17,
18]. The public epitopes are shared by several HLA antigens;
therefore an antibody directed against one of these antigens can
cause a high percentage reactivity. Individual patients can have
one to three different antibodies recognizing different groups of
HLA antigens, thus causing very high percentage reactivities
[17]. The degree of cross-reactivity depends on the titer of
antibody. This can be shown by the use of mouse monoclonal
antibodies generated against class-I HLA antigens [19] or by the
examination of sera at different dilutions from highly sensitized
patients [201. We have found, in vivo, that the reduction of
HLA antibody titer by plasma exchange [201 or extracorporeal
immunoadsorption [21] reduces the number of cross-reactions
and percentage reactivity. The presence of cross-reactive group
antibodies is associated with an increased rate of early graft loss
and certain cross-reactive group combinations, for example,
B7, 22, 27 and B5, 18, 35, with a high rate of rejection [22].
Patients also can have high percentage reactivities because they
have multiple antibodies directed against private determinants
on different HLA class-I molecules. In our experience [20],
approximately 60% of highly sensitized patients have cross-
reactive HLA antibodies, whereas 30% have HLA antibodies
directed against multiple private determinants.
Non-HLA lymphocytotoxic autoantibodies, which are usu-
ally 1gM [9], cause high, broadly reactive percentage reactiv-
ities and occur in approximately 10% of our sensitized patients
awaiting renal transplantation [20]. It has been recognized for
many years that these antibodies do not cause hyperacute
rejection [23] and that transplantation across a positive cross-
match caused by these antibodies is associated with good graft
survival [24, 25]. The antibodies are now readily identified by
pretreating sera with dithiothreitol [261, which inactivates 1gM
but not IgG. Their importance lies in their ability to cause a high
percentage reactivity and to "hide" significant IgG HLA anti-
bodies [27]. They can be in found in patients with systemic
lupus erythematosus [28] and can occur after viral infections,
particularly with cytomegalovirus [29].
Anti-vascular endothelial cell (VEC)-monocyte antibodies
are not detected in conventional CDC tests and therefore
technically (that is, in in-vitro testing) are not important in
sensitized patients. Increasing evidence suggests, however,
that the VEC antibodies play an important role in allograft
rejection. Antibodies directed against VEC antigens are found
in patients with irreversible vascular rejection [30—32], particu-
larly in recipients of HLA-identical allografts. In a multicenter,
retrospective study of 35 HLA-identical, living related allograft
recipients with severe rejection, 83% of the patients who lost
their allograft from rejection had VEC antibodies [32]. Good
evidence suggests that these antibodies cause graft loss and do
not arise as a result of the rejection process [311. They cross-
react with monocytes [32] and can be difficult to detect in the
presence of HLA antibodies. Antibodies directed against mono-
cytes alone are unimportant [32]. Evidence suggests that VEC
antigens are closely linked to the major histocompatibility
complex (MHC) [33, 34] and that DRw6 recipients are more
likely than recipients without DRw6 to develop VEC antibodies
[35]. Using a donor-specific vessel cross-match technique with
donor aorta and vena cava, VEC antibodies can now be
detected prospectively [36]. In a preliminary study of 55 ca-
daver allograft recipients, 6 of 7 patients experiencing early,
irreversible rejection had VEC antibodies [36].
Certain red cell antibodies are lymphocytotoxic and are
therefore detected in CDC assays; hence, these too can cause
"sensitization." These red cell antibodies include Lewis anti-
bodies [37] and I and i antibodies [38]. They are not thought to
be important clinically.
Causes of HLA sensitization
What prompts the formation of HLA antibodies and the
consequent sensitization? These antibodies generally develop
as a result of failed, mismatched transplants, blood transfu-
sions, and multiple pregnancies [39—41]. Often a combination of
these factors is involved, In a series of 2879 patients, failed
transplants were thought to be the most important source of
HLA antibodies, followed by pregnancy and transfusion [41].
After a failed transplant, the increase in sensitization (as judged
by percentage reactivity) depends on the degree of class-I
mismatching with the first transplant [42]. In a study of 449
patients who had lost a graft, the mean increase in percentage
reactivity in the poorly matched group was 45%, whereas in the
well-matched group, the mean increase was 34%. The number
of pregnancies is important, as shown in a study of 578 parous
women; only 23.6% of women with 2 pregnancies had HLA
antibodies, whereas 63% of women with 6 pregnancies had
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HLA antibodies [40]. Transfusions in parous women are par-
ticularly likely to induce sensitization. Opelz et a!, in a study of
737 patients, found that 75% of women who had had 3 or more
pregnancies and who had received 5 units of blood had percent-
age reactivities of at least 50% [391. Women tend to be more
sensitized than are men. In a Council of Europe study of
sensitized patients, 14% of women awaiting their first transplant
were highly sensitized, whereas only 5% of the male patients
studied were highly sensitized [43]. This effect is partly related
to the women's previous pregnancies: of these highly sensitized
patients, 61% had been pregnant, but only 46% of the unsensi-
tized women had been pregnant. With regrafts, this imbalance
disappeared; 31% and 26% of female and male patients, respec-
tively, were highly sensitized. The timing of blood transfusions
also is important, as shown in the early days of HLA typing,
when normal individuals were immunized with HLA antigens to
produce HLA alloantisera [44]. Frequent (weekly), small-vol-
ume transfusions (50 ml) were more efficient in immunizing
patients than were less frequent, larger-volume transfusions
[441; this finding might explain why donor-specific transfusion is
so efficient at inducing HLA antibodies [45]. Few data are
available to explain why some patients have persistently high
percentage reactivities and titers of HLA antibodies, sometimes
for many years. However, Deierhoi and colleagues recently
showed that in many patients, persistently high percentage
reactivities occur as a result of continuing blood transfusion
[46]. The patient we are discussing here is a classic example of
the importance of all these factors. She had several pregnan-
cies, more than 50 transfusions, and she lost a mismatched
transplant.
In 1985, Tongio and colleagues reported spontaneous HLA
antibodies in 1% of normal blood donors who had not been
pregnant [471. These HLA antibodies are weak, mainly 1gM;
interestingly, they are often directed against HLA-B8 [47]. In
1980, Chardonnens and Jeannet found HLA antibodies against
noninherited maternal antigens in newborn babies [48]. The
sera and kidneys of patients after transplantation also contain
HLA antibodies. Although initially the significance of these
antibodies was uncertain, good evidence now suggests that the
development of donor-specific antibodies is associated with
rejection and a poor outcome. Ting and Moms studied sera
taken at 5-day intervals for the first 2 months following initial
cadaveric transplantation in nonsensitized recipients and found
no correlation between the development of donor-specific anti-
bodies and rejection or outcome [491. Nunez et al, however,
reported that the presence of class-I! antibodies before and
after transplantation is associated with a higher incidence of
graft loss [501. Lorden and coworkers demonstrated that anti-
body against a B lymphoid cell line is associated with vascular
rejection and graft loss [51]. Martin Ct al also showed that the
development of panel-reactive and donor-specific antibodies in
a large group of patients is associated with a poor outcome [52].
We found donor-specific antibodies in the sera of highly sensi-
tized patients at the time of allograft rejection [53]. Because
these antibodies can be transient and present in low titer, they
can be missed easily. Cytotoxic HLA antibodies can be eluted
from rejected kidneys. These antibodies are not always donor
specific, and the kidney can act as a nonspecific antibody
"sponge" [54].
Consequences of sensitization
Highly sensitized patients wait considerably longer than do
non-sensitized patients for their transplants. If these patients do
receive allografts, they have a higher incidence of primary
allograft nonfunction (allografts that never function) and poorer
graft survival than do non-sensitized patients. Waiting times for
transplantation in highly sensitized patients vary between 13
and 39 months [11. In the Council of Europe Study, the waiting
time for a highly sensitized patient, from failure of the first graft
to retranspiant, was a mean of 39 months, compared with 22
months in nonsensitized patients [551. Even with the advantage
of a large organ-procurement organization (for example, the
Southeastern Organ Procurement Foundation [SEOPF]), less
than one in 10 highly sensitized patients receives a transplant
within a given year, whereas the probability of a nonsensitized
or moderately sensitized patient receiving a transplant during
this period is high [56]. In France, 21% of the patients in 1983
and 1984 awaiting transplantation were highly sensitized (per-
centage reactivity 75%). During this period, however, only
5.8% (1983) and 2.8% (1984) of the patients who received
transplants were in this highly sensitized group [57].
Primary nonfunction and delayed graft function are associ-
ated with a high percentage reactivity. In a study of 3800 renal
transplants, Sanfilippo et al found that delayed graft function
was associated with both a high peak and current percentage
reactivity and that graft survival was significantly lower in this
group of patients [58]. In a similar, smaller multicenter study
examining the causes of primary allograft nonfunction, a high
current and peak percentage reactivity were major risk factors
[59]. Three-quarters of these grafts were rejected [59].
Good data from the United Kingdom [60] and the United
States [61] show that sensitization has a detrimental effect on
allograft survival. The deleterious effect of sensitization also is
found despite the use of cyclosporine in large, multicenter
studies [62] as well as in smaller, single-center studies. In a
study of 76 patients receiving second transplants, allograft
survival was 35% at one year in the group of patients with
percentage reactivities greater than 50%, and 82% in the group
with percentage reactivities less than 50% [62]. More recent
data suggest, however, that the use of cyclosporine may over-
ride the effect of sensitization [63]. Matas et a! report a 90%
one- and two-year allograft survival in a group of 33 patients
with greater than 90% peak percentage reactivity [64].
Management of sensitized patients
Sensitized patients can successfully receive transplants by
any of the following 3 strategies: (1) use of a well-matched
kidney that does not express the HLA antigens against which
the patient has made antibody; (2) use of "enlightened cross-
matching"; or (3) removal and prevention of the resynthesis of
HLA antibodies. By far the best approach to this problem,
however, is the prevention of sensitization in potential trans-
plant recipients.
Recent advances in transplantation immunosuppression have
improved allograft survival and hopefully will minimize the
most important cause of sensitization, namely, allograft failure.
Because there is little we can do about sensitization arising as a
result of previous pregnancies, I intend to concentrate here on
the role of blood transfusion, Patients with renal failure gener-
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ally are transfused because of hemorrhage, anemia, and be-
cause blood transfusions improve the probability of graft sur-
vival. Although transfusion in patients who are actively
bleeding is essential, there is now little reason to transfuse
patients who have symptomatic anemia. Recombinant human
erythropoietin (rHuEPO) is widely available and highly effec-
tive, although a small proportion of patients receiving this agent
become hypertensive, thrombose dialysis fistulae and grafts, or
have cerebrovascular accidents [65].With increased experience
in the use of rHuEPO, the incidence of these side effects may be
reduced. As yet, however, little evidence suggests that the
elimination of regular transfusion by the use of rHuEPO sub-
stantially reduces percentage reactivity in previously sensitized
patients [66]. A small number of sensitized pediatric patients at
Guy's Hospital who were treated with rHuEPO showed a
steady decline in HLA antibody titer and, to a lesser extent, in
percentage reactivity (Dr. S. Rigden, personal communication).
One certainly would hope that the use of rHuEPO will have a
major impact on the sensitization induced by regular blood
transfusions [46]. In contrast, the depletion of leukocytes from
blood by cotton wool filtration and red cell washing does not
prevent sensitization [671, particularly as red cells can express
class-I antigens [68].
After Opelz et al reported the beneficial effects of blood
transfusion on renal transplant survival in 1973 [69], most
transplant units started to transfuse (and also sensitize) their
patients routinely prior to transplantation [701. It has become
clear, however, that over the past 3 years or so, the "transfu-
sion effect" has become negligible in terms of graft survival, as
confirmed in several large multicenter studies [70, 71] as well as
in single centers [72]. This seeming disappearance of the
"transfusion effect" has been attributed to the overriding
benefits of cyclosporine therapy [70—72]. At present, with the
use of cyclosporine, I do not believe that patients should
receive pretransplant transfusions for the sole purpose of en-
hancing the probability of graft survival. In particular, patients
who are already sensitized or at risk of further sensitization—
for example, parous women—should not be transfused unless it
is clinically indicated.
Clearly the simplest approach to transplantation in a highly
sensitized recipient is finding a well-matched organ that does
not carry the HLA antigens against which the recipient has
generated antibody. Living related donors are the best source
but are available for only a small minority of our patients.
Consequently, special schemes have been developed for finding
well-matched cadaver donors for highly sensitized patients; 11
special programs were started in Europe between 1976 and 1986
[73]. In 1984, the United Kingdom Transplant Service's "Save
Our Sensitised" (SOS) scheme was started. The initial results,
however, have been disappointing, with a 6-month graft sur-
vival of only 56.6% [74]. Scandia Transplant, which has an
organ-sharing program for highly sensitized patients, had com-
parably poor results. They reported a one-year graft survival of
48.6% in 158 patients (most of whom received cyclosporine)
[75]. Slightly better results were reported by SEOPF in 3766
sensitized patients; their one-year graft survival was 63% (with
historically positive cross-match) to 69% (with historically
negative cross match) [76]. The search for an appropriate donor
can be facilitated by predetermining which donor HLA sped-
ficities will give a negative cross-match. Recently Claas et al
described a computer-aided method of predicting allowable
donor HLA antigens by screening recipient sera [77]. Using this
technique, they successfully transplanted organs into 40 pa-
tients (one-year graft survival, 80%), some of whom had been
waiting more than 10 years. The accurate prediction of the
acceptable HLA antigens was greatly aided by the knowledge
of the patient's mother's HLA type; this parameter of screening
was based on the assumption that the patient would have a
negative cross-match with noninherited maternal antigens (be-
cause of tolerance acquired in utero). In a parallel study, 15 of
26 patients had negative cross-matches with noninherited ma-
ternal antigens [78]. This finding indicates that a mother may be
able to induce partial tolerance in her fetus.
Because of the danger of hyperacute rejection when a kidney
is transplanted across a positive cross-match, a negative cross-
match had been an absolute prerequisite before any transplant
operation. Over the past 5 years, this former absolute rule has
lost its grip on us. I use the term "enlightened cross-matching"
to describe the developments in cross-matching that have led to
the successful transplantation of organs in sensitized patients
even in the presence of a positive cross-match or previous
mis-match. Examples include the recognition of the benign
nature of 1gM autoantibodies, which I already mentioned, of the
benign nature of positive cross-matching with historic sera but
negative cross-matching with current sera, and of the accept-
ability of mis-matched HLA antigens on previously failed
grafts. In 1983, Cardella and colleagues described successful
transplantation in a group of patients who had positive cross-
matches with their donors when historic sera were used but
who had negative cross-matches with current sera [791. This
concept is of particular value in the management of sensitized
patients, because at least 50% of them show a decline in
percentage reactivity with time, particularly if further transfu-
sion is avoided [46]. Several studies now have confirmed the
efficacy of Cardella's approach [76, 80, 81]. Extending this
concept, we recently assessed whether a previous mis-match is
important in subsequent retransplantation [821. Provided that
grafts carrying HLA antigens against which the recipient is
known to have made cytotoxic antibody are avoided, and
prophylactic antithymocyte or antilymphocyte globulin is used,
retranspiantation after previous mis-matches has been success-
ful in our hands, with a one-year graft survival of 79%.
The third branch of our management triad is removal and
prevention of the resynthesis of HLA antibodies. In 1983, an
18-year-old patient of ours was in serious trouble. She had had
two unsuccessful living related transplants, she was unable to
tolerate CAPD, and she had virtually no further access sites for
hemodialysis. She was transfusion-dependent, with a percent-
age reactivity persistently greater than 90%; she had had
positive cross-matches with at least 40 potential donors. We
established that her high percentage reactivity was due to a high
titer (1/64) HLA-A2 antibody, which cross-reacted with multi-
ple HLA antigens. We decided to remove her HLA antibody by
plasma exchange and to prevent its resynthesis using cyclo-
phosphamide and steroids. Following such treatment, her anti-
body titer fell to less than 1/10, and her percentage reactivity to
43%; she was given a non-HLA-A2 cadaveric kidney. The
cross-match with her pretreatment sera was positive, but neg-
ative with the posttreatment sera. Her immunosuppresion reg-
imen post transplant consisted of prednisone and azathioprine.
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She experienced no hyperacute rejection and, although she had
two severe rejection episodes, she remains well 7 years later,
with a current plasma creatinine of 105 prnollliter (1.2 mgldl).
No increase in HLA-A2 antibody titer occurred after transplan-
tation, even during her rejection episodes. We were encouraged
to make similar attempts in other patients and, although one
patient died from immunosuppression-induced sepsis, we suc-
cessfully transplanted kidneys into 4 additional patients using
this regimen [20]. We then began to use cyclosporine, and,
because of the high incidence of early rejection, we added a
10-day prophylactic course of antithymocyte globulin, starting
at the time of transplantation.
Extracorporeal immunoadsorption with staphylococcal pro-
tein A is a new technique by which circulating IgG can be
efficiently removed [841. We therefore decided to use immu-
noadsorption rather than plasma exchange [85] and recently
published our results with 10 patients [21]. In our hands, this
technique is an effective method of removing HLA antibodies.
We recently reviewed the outcome of 19 patients whose HLA
antibodies were removed by either plasma exchange or immu-
noadsorption and who have had a successful allograft for a
minimum of one year [86]. Only one graft failed as a result of
rejection. Two patients died (one from sepsis and one from a
myocardial infarction 3 years post transplant). The one-year
patient and graft survival were 94% and 88%, respectively.
These results compare favorably with those obtained using the
conventional "wait for a good match strategy." We select our
patients carefully. Their HLA antibodies are fully characterized
and in general are directed against one or two cross-reactive
groups. We also ensure that the patients are fit enough to
tolerate the immunosuppression. Our approach using both
plasma exchange and immunoadsorption has been used suc-
cessfully by several other groups [87—89]. Limited data suggest
that the prevention of HLA antibody resynthesis depends on
the use of cyclophosphamide. Hillebrand et al were unable to
prevent the resynthesis of HLA antibody using azathioprine (in
3 patients) or cyclosporine (in 2 patients) [901. We used cyclo-
sporine in 4 patients [911. In the 2 patients with relatively low
titers of HLA antibody, we were able to suppress HLA
antibody resynthesis, but in 2 other patients with higher titers,
we were unsuccessful. Most of the deaths in the patients treated
with this technique resulted from infection. Before this tech-
nique can be used more widely, a less toxic method of prevent-
ing antibody resynthesis must be developed. At present, there-
fore, I believe that HLA antibody removal should be reserved
for the fit patient with well-characterized antibodies who needs
urgent transplantation.
How does one manage the sensitized patient after transplan-
tation? As I said earlier, sensitized patients have a higher
incidence of rejection and impaired graft survival when com-
pared with nonsensitized patients. We routinely add a 10-day
course of antithymocyte globulin to our standard regimen of
prednisolone and cyclosporine for our sensitized patients. With
this regimen, we achieve a one- and two-year patient survival
rate of 96% and a one- and two-year graft survival rate of 84%
and 79%, respectively [92]. Similar results with sensitized
patients also have been reported with other regimens using
prophylactic antithymocyte or antilymphocyte globulin. De-
Masi and coworkers recently reported one-year patient and
allograft survival rates of 97.0% and 82.5%, respectively, using
a quadruple immunosuppression regimen [93]. Sommer et al
used antilymphocyte globulin, cyclosporine, and prednisone
sequentially, and obtained a two-year patient and graft survival
of 91% and 72%, respectively [94]. These results are better than
those described earlier [59, 60, 64]; the prophylactic use of
antithymocyte and antilymphocyte globulin possibly improves
graft survival in sensitized patients without significantly in-
creasing the risk of infection or neoplasia. No formal proof
confirms this hypothesis, however, because no randomized,
controlled trial has been performed.
In conclusion, the sensitized patient presents several prob-
lems, none of which is insurmountable, as demonstrated by the
patient discussed today. Improvements in graft survival, the
use of rHuEPO, and the cessation of routine pretransplant
transfusions should soon make sensitization much less problem-
atic than at present.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I always have
thought that patients with any degree of percentage reactivity
are, in fact, sensitized. You have given us certain ranges of
percentage reactivity representing different degrees of sensiti-
zation. What do these ranges of percentage reactivity indicate,
and what is the reproducibility and accuracy of the test?
DR. TAUBE: Your first comment is entirely relevant. The
ranges of percentage reactivity that I have discussed are arbi-
trary. The validity of the percentage reactivity depends on the
size of the panel and the technical excellence and expertise of
the tissue typing laboratory. Small panels can be particularly
misleading. Blood transfusions and viral infections can cause
marked, often transient, fluctuations in an individual patient's
percentage reactivity. It is therefore essential that we measure
a patient's percentage reactivity several times over a period of
time before deciding on the degree of sensitization.
DR. M. MCGEOWN (Professorial Fellow, Queen's University,
Belfast, Northern Ireland): Although the current results of the
United Kingdom Transplant Service's SOS program matching
scheme are disappointing, we hope to improve them by increas-
ing the degree of matching between donor and recipient.
DR. TAUBE: The avoidance of the HLA antigens against
which the recipient has made antibody ensures a certain degree
of matching. Gerhardt Opelz has data showing that good
matching in highly sensitized patients greatly improves graft
survival (personal communication; presented at 1989 EDTA/
ERA Congress in GOteborg, Sweden). But finding a good match
entails a mean wait for a transplant of 4 years.
DR. C. M. LocKwooD (Lecturer in Medicine, University of
Cambridge, Cambridge, England): How long should one use
prophylactic antithymocyte or antilymphocyte globulin after
transplantation in these highly sensitized patients? Do patients
with higher titers of HLA antibodies require larger doses and
extended courses of antithymocyte or antilymphocyte globulin?
DR. TAUBE: We generally give a 10-day course of antithymo-
cyte or antilymphocyte globulin to these patients after trans-
plantation. Little evidence suggests that a 5- or 7-day course is
less effective than a 10-day course, however, We have no
evidence suggesting that the more highly sensitized patients
require more prophylactic antithymocyte or antilymphocyte
globulin.
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DR. A. REES (Consultant Nephrologist, Royal Post Graduate
Medical School, Hammersmith Hospital, London, England):
You made some tantalizing comments about monocyte-endo-
thelial antibodies. One of them was that monocyte antibodies
do not cause rejection; another was that this system is MHC
linked.
DR. TAUBE: This group of antibodies recognizes epitopes
both on endothelial cells and on monocytes. There is good
evidence showing that endothelial cell antibodies cause rejec-
tion and that monocyte antibodies are harmless [32]. Some
evidence suggests that this system is linked to the major
histocompatibility complex [33]. Recently Brasile et al found
that patients who are DRw6+ are more likely to develop
endothelial cell antibodies [35).
DR. G. NEILD (Senior Lecturer, Institute of Urology, Lon-
don): You came out rather strongly against blood transfusions.
One of the pieces of information you cited was that the benefit
in the cyclosporine era is only 5%. Would you like to qualify
this? My understanding from the literature is that if you use
well-matched grafts, there is no benefit. I think the Scandina-
vian group showed this. I thought, however, that transfusion
had a beneficial effect on the survival of poorly matched grafts.
DR. TAUBE: You are correct; the Scandinavian group found
no beneficial effect of matching or pretransplant transfusion on
graft or patient survival in cyclosporine-treated patients [95].
Also, DR matching was associated with a lower incidence of
rejection [95]. I do not think that there was any evidence that
transfusion improved graft survival in the poorly matched
group.
DR. N. MALLICK (Consultant Nephrologist, Royal Infirmary,
Manchester, England): To prevent subsequent sensitization, do
you think we ought to forbid transplantation across certain
HLA mis-matches?
DR. TAUBE: You raise an important point. I think we should
avoid mis-matches with common antigens such as HLA-A2. If
a patient undergoes unsuccessful transplantation with a graft
mis-matched at HLA-A2, and subsequently generates A2 anti-
body, that patient will be able to receive only 50% of the donor
kidneys, as approximately 50% of our donor population is A2+.
DR. M. BOULTON-JONES (Consultant Nephrologist, Royal
Infirmary, Glasgow, Scotland): Does long-term immunosup-
pressive treatment without antibody removal alter the nature of
the HLA antibodies? Does any evidence suggest that these
antibodies are beneficial (that is, anti-idiotypic) rather than
cytotoxic?
DR. TAUBE: I know of no data or evidence showing that
immunosuppressive therapy alone reduces HLA antibody titers
or induces the formation of anti-idiotypic antibodies.
DR. M. YENNING (Lecturer in Medicine, University of New-
castle upon Tyne, Newcastle, England): You suggest that we
should only use rHuEPO and avoid transfusing anemic patients.
Occasionally we have to transfuse our patients. Do you think
we ought to use filters to remove leukocytes and platelets to
prevent sensitization on these occasions?
DR. TAUBE: As I mentioned briefly, unfortunately removal of
leukocytes from whole blood by filters, cotton wool, and red
cell washing does not completely remove them and sensitiza-
tion still results [68]. Red cells also express class-I MHC
antigens [68]. In these situations, it might be worthwhile using
filters to reduce sensitization, but I have no solid evidence to
prove this.
DR. C. PUSEY (Senior Lecturer in Medicine, Royal Post
Graduate Medical School, Hammersmith Hospital): You pre-
sented data showing that approximately one-half of your pa-
tients had a more rapid rebound in HLA antibody titer after
antibody removal than the others. Is there any way of predict-
ing which patients will have a less rapid rebound so that we can
identify the patients who will require less treatment? Does this
group have less rejection after transplantation?
DR. TAUBE: Patients with HLA antibody titers of 1:8 or less
prior to plasma exchange or extracorporeal immunoadsorption
are easy to treat, in that they require less plasma exchange or
immunoadsorption and have a minimal antibody rebound. After
transplantation there is no correlation between the degree of
sensitization and the incidence or severity of rejection.
DR. PUSEY: Is immunoadsorption more effective than plasma
exchange in the removal of HLA antibodies?
DR. TAUBE: There are no formal, controlled data showing
that immunoadsorption is more effective than plasma exchange.
We were unable to remove the HLA antibody from two of our
very heavily sensitized patients by plasma exchange. We could,
however, successfully remove their antibody later with immu-
noadsorption.
DR. J. S. CAMERON (Professor of Nephrology, Guy's Hospi-
tal, London): Have you tried using cyclosporine or other less
toxic substances than cyclophosphamide to prevent antibody
resynthesis, particularly 3 to 4 months post immunoadsorption?
This might avoid the long-term toxicity of cyclophosphamide.
DR. TAUBE: That is a good suggestion. We have not tried
switching to cyclosporine and steroids 3 to 4 months post
immunoadsorption. Stopping the cyclophosphamide at that
time usually results in antibody rebound even if the patient is
neutropenic. We have tried using cyclosporine and steroids at
the time of immunoadsorption to prevent antibody resynthesis,
but we have had only limited success [911.
DR. M. JONES (Lecturer, Department of Medicine, University
of Aberdeen, Aberdeen, Scotland): In transplantation with
living related donors, azathioprine reduces the incidence of
sensitization following donor-specific transfusion by approxi-
mately 50%. Also, some data suggest that cyclosporine reduces
the incidence of sensitization by random third-party transfusion
in cadaveric transplantation [96]. We also have preliminary,
unpublished data suggesting that cyclosporine and third-party
transfusion might stimulate the formation of anti-idiotypic an-
tibodies. Do you think that we ought to give cyclosporine with
blood transfusions to prevent sensitization?
DR. TAUBE: I agree that recipients of living related trans-
plants who receive donor-specific transfusions should receive
azathioprine to prevent the development of cytotoxic antibod-
ies. I am aware of your group's work with third-party transfu-
sions and cyclosporine. As far as I know, you have only treated
small numbers of patients, several of whom have yet to receive
transplants. My view is that if we persist in transfusing patients
before transplantation, any relatively harmless maneuver that
might reduce the incidence of sensitization is of value.
DR. A. WING (Consultant Physician, St. Thomas' Hospital,
London): Forgive this question, but I would like to discuss the
cost of HLA antibody removal by immunoadsorption. You
mentioned that it was expensive. Do you have any details?
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DR. TAUBE: A pair of immunoadsorption protein A columns
currently costs approximately £3600 ($5735). The buffers, lines,
and plasma filters cost another £1500 ($2390). The equivalent
amount of plasma exchange costs slightly less. However, the
same pair of protein A columns can be used for an individual
patient for as long as one year. Therefore immunoadsorption
will be cheaper than plasma exchange if multiple courses of
treatment are needed.
DR. HARRINGTON: You mentioned that the scheme of HLA
antibody removal and prevention of its resynthesis could be
applied to approximately two-thirds of your highly sensitized
patients. What about the other one-third?
DR. TAUBE: The group of patients you refer to presents a
difficult problem because they have antibodies against multiple
HLA antigens. Their high percentage reactivities are not caused
by antibody directed against cross-reactive groups. Therefore,
HLA antibody removal does not work in this group of patients.
Occasionally, however, we can remove all the antibody di-
rected against a particular antigen. We did this in one patient
who had antibody against multiple HLA antigens, including A2
[211. We were able to remove all his A2 antibody and prevent its
resynthesis with cyclophosphamide and steroids, One year
later, he successfully received an A2-i- kidney, which is func-
tioning well 18 months post transplant. This maneuver might be
a good approach in patients with multiple HLA antibodies
against multiple HLA antigens.
DR. J. DONOHOE (Consultant in Nephrology, Beaumont
Hospital, Dublin, Ireland): Is living-related-donor transplanta-
tion a good option for highly sensitized patients?
DR. TAUBE: Yes, particularly if the donor and recipient are
well matched. Unfortunately, such a scenario is uncommon.
Da. HARRINOTON: What are the results of other groups doing
comparable work on HLA antibody removal?
DR. TAUBE: Several other groups have used plasma exchange
to remove HLA antibody. In general they have done well [87,
88], particularly when the results are compared with those
obtained by the organ matching programs [74, 751. Immuno
sorption is a relatively new technique, and as yet there are few
data other than our own.
DR. R. GABRIEL (Consultant Physician, St. Mary's Hospital,
London): You implied that transplantation is the only treatment
of chronic renal failure. There must be situations in which
chronic dialysis is the better choice.
DR. TAUBE: Transplantation provides the cheapest and most
effective form of treatment for patients with end-stage renal
failure. Certain patients—for example, diabetics with extensive
vascular and ischemic heart disease—do badly after transplan-
tation and probably are best left on dialysis. However, highly
sensitized patients often are young and fit and are otherwise
ideal candidates for transplantation. Because transplantation
has become so successful, the real problem with it is the
shortage of donor kidneys.
Reprint requests to Dr. D. Taube, Transplant Unit, Clarence Wing
St. Mary's Hospital, Paddingion, London W2 INY, England
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